Annual check-ups save lives by detecting prostate issues early, yet many men avoid these crucial tests due to fear or misconceptions. Prostate health ...

After skin cancer, prostate cancer is the most common cancer in men in the US. A new treatment is giving men more options.

Researchers conducted a post hoc, retrospective, cross-sectional analysis of 182 patients with recurrent prostate cancer ...

Kearney Urology Center has reported a 50% reduction in biopsies since adopting EpiSwitch® PSE, a new accurate blood test for prostate cancer. The reduction is down to the marked improvement offered by ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...

Overall, PSMA-PET/CT detected distant metastasis in 84 of 182 cases (46%) that were negative by other types of imaging, ...

First, a high level of PSA screening occurred in the control ... cancer mortality might be the result of better-than-expected treatment for prostate cancer (80–90% of diagnosed men underwent ...

New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent ...

A recent study published on December 19, 2024, in the ExRNA journal highlights research from the Novosibirsk Institute of ...

Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) frequently detects metastatic disease missed by conventional imaging, investigators report.

Biocon's biosimilar Ustekinumab receives regulatory approval in Japan, with Yoshindo Inc. handling commercialization and ...

Biocon shares rose 9% to ₹389, driven by positive developments including Japanese approval for its biosimilar Ustekinumab.